Wells Fargo raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $82 and keeps an Overweight rating on the shares. Following a strong 2025, the firm sees further value creation on multiple catalysts in 2026, including Phase 3 readouts for bepirovirsen in cHBV, pelacarsen in Lp(a) and WAINUA in ATTR-CM.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Cathie Wood Wraps Up 2025 with New Biotech Buys — Here’s What It Sold
- Cathie Wood Closes Out 2025 with a Rocket Lab (RKLB) Trim and Fresh Biotech Bets
- IONS, IBTA, IRDM: Cathie Wood Continues Trimming Stakes in Ionis, Ibotta, and Iridium Stocks
- Ionis Pharmaceuticals price target raised to $95 from $82 at RBC Capital
- Arrowhead price target raised to $100 from $70 at Piper Sandler